{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:31:12Z","timestamp":1785796272777,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Germline <jats:italic>TP53<\/jats:italic> gene variants are intricately linked to Li-Fraumeni syndrome, a rare and aggressive hereditary cancer syndrome. This study investigated the frequency and spectrum of <jats:italic>TP53<\/jats:italic> pathogenic variants associated with Li-Fraumeni syndrome in a large cohort of mainly breast cancer patients from Russia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study analyzed 3,455 genomic DNA samples from cancer patients using next-generation sequencing panels and whole-genome sequencing. Clinically significant <jats:italic>TP53<\/jats:italic> variants were identified and validated using Sanger sequencing. The clinical and family history characteristics of patients with <jats:italic>TP53<\/jats:italic> variants were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The analysis identified 13 (0.4%) individuals with clinically significant germline <jats:italic>TP53<\/jats:italic> variants, all of whom were females with either unilateral breast cancer or breast cancer as part of multiple primary malignant neoplasms. The average age of breast cancer manifestation was 39.9\u00a0years, with a median of 36\u00a0years. Only 38.5% of the <jats:italic>TP53<\/jats:italic> mutation carriers met the modified Chompret criteria for <jats:italic>TP53<\/jats:italic> testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The findings underscore the necessity of thorough phenotype and family history analysis in genetic counseling to effectively diagnose LFS, and emphasize the importance of identifying <jats:italic>TP53<\/jats:italic> variant carriers for developing treatment strategies, prognosis, and monitoring, as well as for identifying high-risk family members. The study also highlights that the current guidelines fail to identify over half of the <jats:italic>TP53<\/jats:italic> mutation carriers, suggesting the need for a more comprehensive approach to genetic testing in suspected hereditary cancer cases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13053-025-00307-w","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:04:27Z","timestamp":1739793867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing germline TP53 mutations in cancer patients: insights into Li-Fraumeni syndrome and genetic testing guidelines"],"prefix":"10.1186","volume":"23","author":[{"given":"Anastasiia","family":"Danishevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Fedorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bodunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Makarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Byakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vsevolod","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Litvinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Nikolaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Efimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Osinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Lisitsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Khakhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Shipulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Nasedkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuykum","family":"Shumilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airat","family":"Bilyalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Shagimardanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shigapova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Nemtsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesya","family":"Sagaydak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Woroncow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Gadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Khatkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"1","key":"307_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCO.0000000000000423","volume":"30","author":"A Amadou","year":"2018","unstructured":"Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30(1):23\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"23","key":"307_CR2","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673\u201381.","journal-title":"Cancer"},{"issue":"7","key":"307_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s12094-019-02236-2","volume":"22","author":"P Gargallo","year":"2020","unstructured":"Gargallo P, Y\u00e1\u00f1ez Y, Segura V, Juan A, Torres B, Balaguer J, et al. Li-Fraumeni syndrome heterogeneity. Clin Transl Oncol. 2020;22(7):978\u201388.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"307_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","volume":"167","author":"K Schon","year":"2018","unstructured":"Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167(2):417\u201323.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"307_CR5","first-page":"1091","volume":"4","author":"M Miller","year":"2016","unstructured":"Miller M, Shirole N, Tian R, Pal D, Sordella R. The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants. J Cancer Biol Res. 2016;4(4):1091.","journal-title":"J Cancer Biol Res"},{"issue":"1","key":"307_CR6","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"307_CR7","first-page":"57","volume":"19","author":"S Surget","year":"2013","unstructured":"Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;19(7):57\u201368.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"307_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jmedgenet-2020-106876","volume":"58","author":"H Hanson","year":"2020","unstructured":"Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, et al. UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. 2020;58(2):135\u20139.","journal-title":"J Med Genet"},{"issue":"10","key":"307_CR9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, Hoogerbrugge N, et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379\u201386.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"307_CR10","doi-asserted-by":"publisher","first-page":"16614","DOI":"10.1038\/s41598-020-73282-y","volume":"10","author":"C Mathias","year":"2020","unstructured":"Mathias C, Bortoletto S, Centa A, Komechen H, Lima RS, Fonseca AS, et al. Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability. Sci Rep. 2020;10(1):16614.","journal-title":"Sci Rep"},{"issue":"10","key":"307_CR11","first-page":"1461","volume":"11","author":"A Bilyalov","year":"2022","unstructured":"Bilyalov A, Nikolaev S, Shigapova L, Khatkov I, Danishevich A, Zhukova L, et al. Application of Multigene Panels Testing for Hereditary Cancer Syndromes. Biology (Basel). 2022;11(10):1461.","journal-title":"Biology (Basel)"},{"issue":"9","key":"307_CR12","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.3390\/ijms24097940","volume":"24","author":"M Makarova","year":"2023","unstructured":"Makarova M, Nemtsova M, Danishevich A, Chernevskiy D, Belenikin M, Krinitsina A, et al. The CFTR Gene Germline Heterozygous Pathogenic Variants in Russian Patients with Malignant Neoplasms and Healthy Carriers: 11,800 WGS Results. Int J Mol Sci. 2023;24(9):7940.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"307_CR13","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.3390\/ijms24097940","volume":"24","author":"M Makarova","year":"2023","unstructured":"Makarova M, Nemtsova M, Danishevich A, et al. The CFTR Gene Germline Heterozygous Pathogenic Variants in Russian Patients with Malignant Neoplasms and Healthy Carriers: 11,800 WGS Results. Int J Mol Sci. 2023;24(9):7940.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"307_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/cancers16010085","volume":"16","author":"A Bilyalov","year":"2023","unstructured":"Bilyalov A, Danishevich A, Nikolaev S, et al. Novel Pathogenic Variants in Hereditary Cancer Syndromes in a Highly Heterogeneous Cohort of Patients: Insights from Multigene Analysis. Cancers (Basel). 2023;16(1):85.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"307_CR15","doi-asserted-by":"publisher","first-page":"16234","DOI":"10.18632\/oncotarget.24611","volume":"9","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Watanabe M, Yamashita K. Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget. 2018;9(22):16234\u201347.","journal-title":"Oncotarget"},{"issue":"3","key":"307_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176(3):535-548.e24. https:\/\/doi.org\/10.1016\/j.cell.2018.12.015.","journal-title":"Cell"},{"issue":"10","key":"307_CR17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381\u20137.","journal-title":"Nat Genet"},{"issue":"14","key":"307_CR18","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"307_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ijc.32424","volume":"146","author":"S Sheng","year":"2020","unstructured":"Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, et al. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. Int J Cancer. 2020;146(2):487\u201395.","journal-title":"Int J Cancer"},{"issue":"12","key":"307_CR20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/humu.23656","volume":"39","author":"C Fortuno","year":"2018","unstructured":"Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39(12):1764\u201373.","journal-title":"Hum Mutat"},{"issue":"7","key":"307_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cncr.28507","volume":"120","author":"S Hettmer","year":"2014","unstructured":"Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014;120(7):1068\u201375.","journal-title":"Cancer"},{"issue":"9","key":"307_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295\u2013305.","journal-title":"Lancet Oncol"},{"issue":"2","key":"307_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31601","volume":"144","author":"JY Li","year":"2019","unstructured":"Li JY, Jing R, Wei H, Wang M, Xiaowei Q, Liu H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int J Cancer. 2019;144(2):281\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"307_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00381-020-04885-z","volume":"37","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wu J, Li W, Li J, Liu R, Yang B, et al. Retrospective investigation of hereditary syndromes in patients with medulloblastoma in a single institution. Childs Nerv Syst. 2021;37(2):411\u20137.","journal-title":"Childs Nerv Syst"},{"issue":"10","key":"307_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/jmg.2004.029538","volume":"42","author":"D Baralle","year":"2005","unstructured":"Baralle D, Baralle M. Splicing in action: assessing disease causing sequence changes. J Med Genet. 2005;42(10):737\u201348.","journal-title":"J Med Genet"},{"issue":"1","key":"307_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-025-01429-5","volume":"17","author":"P Rofes","year":"2025","unstructured":"Rofes P, Castillo-Manzano C, Men\u00e9ndez M, et al. TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate. Genome Med. 2025;17(1):3.","journal-title":"Genome Med"},{"issue":"1","key":"307_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1186\/s12885-020-07476-y","volume":"20","author":"A Kwong","year":"2020","unstructured":"Kwong A, Shin VY, Ho CYS, Au CH, Slavin TP, Weitzel JN, et al. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020;20(1):1053.","journal-title":"BMC Cancer"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-025-00307-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:04:29Z","timestamp":1739793869000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-025-00307-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1186\/s13053-025-00307-w","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee name: The Local Ethics Committee of the Moscow Clinical Scientific Center, named after A. S. Loginov. Approval code: 46326\/15.1. Approval date: 10 May 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}